TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Biovest Meets Skeptic's Requirements for 'The Next Dendreon' - Part 3 James Hill, MD submits: This series investigates how the BiovaxID lymphoma vaccine may win FDA approval to make Biovest (BVTI.PK) “the next Dendreon,” according to criteria elaborated in David Miller’s Minyanville article of the same name. Dendreon (DNDN), you will recall, is the first company ever to achieve FDA approval of a cancer vaccine, with it flagship product, Provenge (sipuleucel-T). Part 1 of this article dealt with vaccine manufacturing issues, Part 2 with multi-antigen targeting by cancer vaccines.Complete Story » seekingalpha.com |
EPA Focuses on Poor, Minorities The Environmental Protection Agency outlined a plan for placing special emphasis on the health of low-income and minority populations when drafting rules. online.wsj.com |
Do Not Get Caught Short Small or Mid Cap Tech There’s a very simple equation taking place in this market right now and I wouldn’t be fighting against it. Here’s how it goes. Big cap tech firms have an enormous amount of cash on their balance sheets and are coming off some of the best couple of quarters they’ve ever had. Growth has been very good for these companies, but they are obviously scared that in a weakening domestic economy it may be hard to keep up the page organically.Complete Story » seekingalpha.com |
Sanofi-Aventis to Lay Off 1,700 U.S. Employees Sanofi-Aventis said it is eliminating 1,700 jobs in its U.S. pharmaceutical business in a restructuring triggered by generic competition and other factors. online.wsj.com |
Tengion to Host Conference Call to Provide a Business Update and Report Third Quarter 2010 Financial Results on November 1, 2010 [PR Newswire] - Tengion, Inc. , a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, November 1, 2010 at 5:00 p.m. EDT to provide a business update and discuss its third quarter 2010 financial results. Â us.rd.yahoo.com |